{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-202865","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2025-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.776059+00:00","generated_at":"2026-05-17T06:36:30.300077+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"aTyr Pharma Phase 3 EFZO-FIT study misses primary endpoint in pulmonary sarcoidosis","bullets":["Primary endpoint: change from baseline in mean daily OCS dose at week 48; p=0.3313 (2.79 mg efzofitimod vs 3.52 mg placebo).","Nominal KSQ-Lung score improvement for 5.0 mg/kg vs placebo (p=0.0479); steroid withdrawal with KSQ-Lung improvement p=0.0199.","FVC maintained; safety consistent with prior trials; company plans to engage FDA on path forward.","Study enrolled 268 patients; hierarchical testing stopped after primary miss; all subsequent p-values nominal."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-202865","json":"https://secwatch.observer/filing/0001193125-25-202865.json","markdown":"https://secwatch.observer/filing/0001193125-25-202865.md","text":"https://secwatch.observer/filing/0001193125-25-202865.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000119312525202865/0001193125-25-202865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000119312525202865/atyr-20250915.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:36:30.300077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}